EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Recent Advances in Development of Kaposi's Sarcoma‐Associated Herpesvirus‐Latency‐Associated Nuclear Antigen Targeted Therapies

Zhiqiang Qin iD, Lu Dai

Journal of Medical Virology · 2025

DOI: 10.1002/jmv.70718 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Medical Virology, 2025. Verfasst von Zhiqiang Qin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA. Hauptthemen laut MEDLINE: Herpesvirus 8, Human, Antigens, Viral, Nuclear Proteins, Sarcoma, Kaposi. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDCR NIH HHS, NIAID NIH HHS, This study was supported by NIH R21AI186566, R03DE034653, the Winthrop P. Rockefeller Cancer Institute New Faculty Start-up Fund, the Arkansas Bioscience Insti….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kaposi's Sarcoma‐associated Herpesvirus (KSHV, also named as Human Herpesvirus 8, HHV‐8) represents a principal causative agent of several cancers arising in patients with compromised immune systems. The latency‐associated nuclear antigen (LANA), encoded by KSHV ORF73, is required for replication, persistence, and gene transcription of the viral KSHV genome. Also, LANA functions contribute to KSHV‐induced angiogenesis, oncogenesis, cell proliferation and immune escape. Therefore, LANA represents a promising target for the discovery and development of new anti‐KSHV drugs, although no specific treatments directed against KSHV latency are available. In the current review, we summarize recent advances in development of KSHV‐LANA targeted therapies and discuss existed challenging as well as potential concerns.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Herpesvirus 8, HumanAntigens, ViralNuclear ProteinsSarcoma, KaposiVirus LatencyAntiviral AgentsHerpesviridae InfectionsHumans

Stichwörter der Autor:innen

KSHVLANAoncogenic virustargeted therapy

Substanzen

latency-associated nuclear antigenAntigens, ViralNuclear ProteinsAntiviral Agents

Autor:innen und Institutionen

  • Department of Pathology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.

ORCID-Profile: Zhiqiang Qin

Förderung

  • NIDCR NIH HHS
  • NIAID NIH HHS
  • This study was supported by NIH R21AI186566, R03DE034653, the Winthrop P. Rockefeller Cancer Institute New Faculty Start-up Fund, the Arkansas Bioscience Insti…

Zitieren

APA

Qin, Z., & Dai, L. (2025). Recent Advances in Development of Kaposi's Sarcoma‐Associated Herpesvirus‐Latency‐Associated Nuclear Antigen Targeted Therapies. Journal of Medical Virology. https://doi.org/10.1002/jmv.70718

Vancouver

Qin Z, Dai L. Recent Advances in Development of Kaposi's Sarcoma‐Associated Herpesvirus‐Latency‐Associated Nuclear Antigen Targeted Therapies. Journal of Medical Virology. 2025. doi:10.1002/jmv.70718

BibTeX
@article{Qin2025,
  author = {Qin, Zhiqiang and Dai, Lu},
  title = {Recent Advances in Development of Kaposi's Sarcoma‐Associated Herpesvirus‐Latency‐Associated Nuclear Antigen Targeted Therapies},
  journal = {Journal of Medical Virology},
  year = {2025},
  doi = {10.1002/jmv.70718}
}
Kostenlos starten →